An Open-Label, Multicentre, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumours or With B-cell Lymphomas

Official Title

An Open-Label, Multicentre, Phase 1/2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumours or With B-cell Lymphomas

Summary:

This is a multicentre, open-label, Phase 1/2 study that is being conducted in two parts. The Phase 1 portion (closed to accrual as of January 25, 2016) comprises dose escalation and establishment of the recommended Phase 2 dose (RP2D) when EPZ-6438 (E7438) is given BID (twice daily) orally on a continuous basis. Additionally, in separate cohorts in Phase 1, the effect of food on the bioavailability of EPZ-6438 as well as the drug-drug interaction (DDI) potential of EPZ-6438 are being evaluated. The Phase 2 part was initiated after determining the RP2D. Phase 2 enrolls subjects with DLBCL and FL for the determination of efficacy and safety of EPZ-6438 in 5 separate cohorts determined by centrally confirmed histology, cell of origin (COO), and EZH2 mutation status.

Trial Description

Primary Outcome:

  • Maximum tolerated dose (MTD) (Phase 1 only)
  • Objective response rate (ORR; complete response + partial response [CR + PR]) (Phase 2)
Secondary Outcome:
  • The effect of a high fat meal on the bioavailability of EPZ-6438 (Phase 1)
  • The effect of EPZ-6438 on exposure of midazolam, a CYP3A4 substrate
  • To assess the preliminary activity of EPZ-6438 (Phase 1)
  • The effect of EPZ-6438 on progression-free survival (PFS) (Phase 2)
  • The effect of EPZ-6438 on duration of response (DOR) (Phase 2)
  • The safety and tolerability of EPZ-6438 administered BID orally, continuously in 28-day cycles (Phase 1 and Phase 2)
  • The pharmacokinetic (PK) profile of EPZ-6438 (Phase 1 and Phase 2)
  • The effect of EPZ-6438 on overall survival (OS)

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society